Literature DB >> 25901559

Health risks from computed tomographic screening.

Seth B Krantz1, Bryan F Meyers2.   

Abstract

Results of the recent National Lung Cancer Screening Trial show a significant survival benefit for annual screening with a low-dose computed tomographic (CT) scan in high-risk individuals. This result has led the US Preventive Services Task Force to recommend annual low-dose CT scans for this at-risk population. Less well characterized are the risks from screening. The primary risks from screening are radiation exposure, false-positive results and unnecessary diagnostic and therapeutic procedures, overdiagnosis and overtreatment, and increased psychological distress. This article reviews these risks, which must be considered and weighed against the benefits when discussing enrollment with patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lung cancer; Overdiagnosis; Risks; Screening

Mesh:

Year:  2015        PMID: 25901559     DOI: 10.1016/j.thorsurg.2014.11.003

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  3 in total

Review 1.  Risk factors assessment and risk prediction models in lung cancer screening candidates.

Authors:  Mariusz Adamek; Ewa Wachuła; Sylwia Szabłowska-Siwik; Agnieszka Boratyn-Nowicka; Damian Czyżewski
Journal:  Ann Transl Med       Date:  2016-04

2.  American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

Authors:  M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad
Journal:  Blood Adv       Date:  2020-04-28

3.  Non-invasive Detection of Exosomal MicroRNAs via Tethered Cationic Lipoplex Nanoparticles (tCLN) Biochip for Lung Cancer Early Detection.

Authors:  Chang Liu; Eric Kannisto; Guan Yu; Yunchen Yang; Mary E Reid; Santosh K Patnaik; Yun Wu
Journal:  Front Genet       Date:  2020-03-20       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.